drugset / Trial / NCT06161844

Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus

NCT06161844

Phase 3 Completed 506 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.

Timeline

Start
2024-02-23
Primary completion
2025-05-14
Completion
2025-05-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide 1 mg Subcutaneous